Concord Wealth Partners’s Pacific Biosciences PACB Stock Holding History

Concord Wealth Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23	Closed	-$188	–	1157
2022 Q4	$188	Buy	+23	New	+$198	﹤0.01%	1206
2022 Q3	–	Sell	-93	Closed	–	–	826
2022 Q2	$0	Sell	93 -1,576	-94%	-$9.58K	﹤0.01%	1337
2022 Q1	$15K	Sell	1,669 -1,659	-50%	-$19.1K	﹤0.01%	690
2021 Q4	$68K	Buy	3,328 +2,295	+222%	+$55.4K	0.02%	391
2021 Q3	$26K	Sell	1,033 -1,616	-61%	-$47.9K	0.01%	335
2021 Q2	$93K	Sell	2,649 -495	-16%	-$14.4K	0.03%	248
2021 Q1	$105K	Buy	3,144 +3,048	+3,175%	+$107K	0.04%	215
2020 Q4	$2K	Buy	+96	New	+$1.63K	﹤0.01%	555

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Concord Wealth Partners's PACB Position: Q1 2023 in Review

Concord Wealth Partners sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 23 shares — an estimated $188 sold.

Concord Wealth Partners first reported a position in PACB in Q4 2020 and held it in 8 quarters. The position peaked at $105K in Q1 2021. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

Concord Wealth Partners reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
Concord Wealth Partners sold 23 Pacific Biosciences shares in Q1 2023, an estimated $188.
Concord Wealth Partners first reported a position in Pacific Biosciences in Q4 2020 and held it in 8 quarters.
Concord Wealth Partners's Pacific Biosciences position peaked at $105K in Q1 2021.
259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Concord Wealth Partners's 13F filing for Q1 2023, filed 26 Apr 2023.